Table of Contents
Chapter 1. Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Definitions
1.1.1.1 Product Segment
1.1.1.2 End-Use Segment
1.1.1.3 Application Segment
1.2 Regional Scope
1.3 Estimates and Forecast Timeline
1.4 Objectives
1.4.1 Objective – 1
1.4.2 Objective – 2
1.4.3 Objective – 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 Gvr’s Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List of Secondary Sources
1.11 List of Abbreviations
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Product and Application Snapshot
2.3. End-use Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Emergence of multiplexed immunohistochemistry
3.4.2. Implementation of automation and machine learning in IHC
3.4.3. Increase in prevalence of cancer
3.5. Market Restraint Analysis
3.5.1. High instrument cost
3.5.2. Limitations associated with IHC technique
3.6. Industry Challenges
3.6.1. Quality assurance and standardization-related challenges
3.6.2. Limited scope for multiple evaluations
3.7. Business Environment Analysis
3.7.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.7.2. Porter’s Five Forces Analysis
3.8. COVID-19 Impact Analysis
Chapter 4. Immunohistochemistry Market: Segment Analysis by Product, 2018 – 2030 (USD Million)
4.1. Immunohistochemistry Market: Product Movement Analysis
4.2. Immunohistochemistry Market: Product Estimates and Forecasts, By Application (USD Million)
4.3. Antibodies
4.3.1. Antibodies Market, 2018 – 2030 (USD Million)
4.3.2. Primary Antibodies
4.3.2.1. Primary Antibodies Market, 2018 – 2030 (USD Million)
4.3.3. Secondary Antibodies
4.3.3.1. Secondary Antibodies Market, 2018 – 2030 (USD Million)
4.4. Equipment
4.4.1. Equipment Market, 2018 – 2030 (USD Million)
4.4.2. Slide Staining Systems
4.4.2.1. Slide Staining Systems Market, 2018 – 2030 (USD Million)
4.4.3. Tissue Microarrays
4.4.3.1. Tissue Microarrays Market, 2018 – 2030 (USD Million)
4.4.4. Tissue Processing Systems
4.4.4.1. Tissue Processing Systems Market, 2018 – 2030 (USD Million)
4.4.5. Slide Scanners
4.4.5.1. Slide Scanners Market, 2018 – 2030 (USD Million)
4.4.6. Others
4.4.6.1. Others Market, 2018 – 2030 (USD Million)
4.5. Reagents
4.5.1. Reagents Market, 2018 – 2030 (USD Million
4.5.2. Histological Stains
4.5.2.1. Histological Stains Market, 2018 – 2030 (USD Million)
4.5.3. Blocking Sera And Reagents
4.5.3.1. Blocking Sera and Reagents Market, 2018 – 2030 (USD Million)
4.5.4. Chromogenic Substrates
4.5.4.1. Chromogenic Substrates Market, 2018 – 2030 (USD Million)
4.5.5. Fixation Reagents
4.5.5.1. Fixation Reagents Market, 2018 – 2030 (USD Million)
4.5.6. Organic Solvents
4.5.6.1. Organic Solvents Market, 2018 – 2030 (USD Million)
4.5.7. Proteolytic Enzymes
4.5.7.1. Proteolytic Enzymes Market, 2018 – 2030 (USD Million)
4.5.8. Diluents
4.5.8.1. Diluents Market, 2018 – 2030 (USD Million)
4.5.9. Others
4.5.9.1. Others Market, 2018 – 2030 (USD Million)
4.6. Kits
4.6.1. Kits Market, 2018 – 2030 (USD Million)
Chapter 5. Immunohistochemistry Market: Segment Analysis by Application, 2018 – 2030 (USD Million
5.1. Immunohistochemistry Market: Application Movement Analysis
5.2. Immunohistochemistry Market: Application Estimates and Forecasts, By Application (USD Million)
5.3. Diagnostics
5.3.1. Diagnostics Market, 2018 – 2030 (USD Million)
5.3.2. Cancer
5.3.3. Cancer Market, 2018 – 2030 (USD Million)
5.3.4. Infectious Diseases
5.3.4.1. Infectious Diseases Market, 2018 – 2030 (USD Million)
5.3.5. Cardiovascular Diseases
5.3.5.1. Cardiovascular Diseases Market, 2018 – 2030 (USD Million)
5.3.6. Autoimmune Diseases
5.3.6.1. Autoimmune Diseases Market, 2018 – 2030 (USD Million)
5.3.7. Diabetes Mellitus
5.3.7.1. Diabetes Mellitus Market, 2018 – 2030 (USD Million)
5.3.8. Nephrological Diseases
5.3.8.1. Nephrological Diseases Market, 2018 – 2030 (USD Million)
5.4. Research
5.4.1. Research Market, 2018 – 2030 (USD Million)
Chapter 6. Immunohistochemistry Market: Segment Analysis by End-use, 2018 – 2030 (USD Million)
6.1. Immunohistochemistry Market: End-use Movement Analysis
6.2. Immunohistochemistry Market: End-use Estimates and Forecasts, By Application (USD Million)
6.3. Hospitals & Diagnostic Laboratories
6.3.1. Hospitals & Diagnostic Laboratories Market, 2018 – 2030 (USD Million)
6.4. Research Institutes
6.4.1. Research Institutes Market, 2018 – 2030 (USD Million)
6.5. Others
6.5.1. Others Market, 2018 – 2030 (USD Million)
Chapter 7. Immunohistochemistry Market: Regional Analysis, 2018 – 2030 (USD Million)
7.1. Immunohistochemistry Market Share By Region, 2022 & 2030
7.2. North America
7.2.1. SWOT Analysis
7.2.2. North America Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.2.3. U.S.
7.2.3.1. Key Country Dynamics
7.2.3.2. Target Disease Prevalence
7.2.3.3. Competitive Scenario
7.2.3.4. Regulatory Framework
7.2.3.5. Reimbursement Scenario
7.2.3.6. U.S. Immunohistochemistry Market, 2018 – 2030 (USD MILLION)
7.2.4. Canada
7.2.4.1. Key Country Dynamics
7.2.4.2. Target Disease Prevalence
7.2.4.3. Competitive Scenario
7.2.4.4. Regulatory Framework
7.2.4.5. Reimbursement Scenario
7.2.4.6. Canada Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.3. Europe
7.3.1. SWOT Analysis
7.3.2. Europe Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Target Disease Prevalence
7.3.3.3. Competitive Scenario
7.3.3.4. Regulatory Framework
7.3.3.5. Reimbursement Scenario
7.3.3.6. Germany Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.3.4. UK
7.3.4.1. Key Country Dynamics
7.3.4.2. Target Disease Prevalence
7.3.4.3. Competitive Scenario
7.3.4.4. Regulatory Framework
7.3.4.5. Reimbursement Scenario
7.3.4.6. UK Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.3.5. France
7.3.5.1. Key Country Dynamics
7.3.5.2. Target Disease Prevalence
7.3.5.3. Competitive Scenario
7.3.5.4. Regulatory Framework
7.3.5.5. Reimbursement Scenario
7.3.5.6. France Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.3.6. Italy
7.3.6.1. Key Country Dynamics
7.3.6.2. Target Disease Prevalence
7.3.6.3. Competitive Scenario
7.3.6.4. Regulatory Framework
7.3.6.5. Reimbursement Scenario
7.3.6.6. Italy Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.3.7. Spain
7.3.7.1. Key Country Dynamics
7.3.7.2. Target Disease Prevalence
7.3.7.3. Competitive Scenario
7.3.7.4. Regulatory Framework
7.3.7.5. Reimbursement Scenario
7.3.7.6. Spain Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.3.8. Denmark
7.3.8.1. Key Country Dynamics
7.3.8.2. Target Disease Prevalence
7.3.8.3. Competitive Scenario
7.3.8.4. Regulatory Framework
7.3.8.5. Reimbursement Scenario
7.3.8.6. Denmark Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.3.9. Sweden
7.3.9.1. Key Country Dynamics
7.3.9.2. Target Disease Prevalence
7.3.9.3. Competitive Scenario
7.3.9.4. Regulatory Framework
7.3.9.5. Reimbursement Scenario
7.3.9.6. Sweden Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.3.10. Norway
7.3.10.1. Key Country Dynamics
7.3.10.2. Target Disease Prevalence
7.3.10.3. Competitive Scenario
7.3.10.4. Regulatory Framework
7.3.10.5. Reimbursement Scenario
7.3.10.6. Norway Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.4. Asia Pacific
7.4.1. SWOT Analysis
7.4.2. Asia Pacific Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Competitive Scenario
7.4.3.4. Regulatory Framework
7.4.3.5. Reimbursement Scenario
7.4.3.6. Japan Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.4.4. China
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Competitive Scenario
7.4.4.4. Regulatory Framework
7.4.4.5. Reimbursement Scenario
7.4.4.6. China Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.4.5. India
7.4.5.1. Key Country Dynamics
7.4.5.2. Target Disease Prevalence
7.4.5.3. Competitive Scenario
7.4.5.4. Regulatory Framework
7.4.5.5. Reimbursement Scenario
7.4.5.6. India Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.4.6. South Korea
7.4.6.1. Key Country Dynamics
7.4.6.2. Target Disease Prevalence
7.4.6.3. Competitive Scenario
7.4.6.4. Regulatory Framework
7.4.6.5. Reimbursement Scenario
7.4.6.6. South Korea Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.4.7. Australia
7.4.7.1. Key Country Dynamics
7.4.7.2. Target Disease Prevalence
7.4.7.3. Competitive Scenario
7.4.7.4. Regulatory Framework
7.4.7.5. Reimbursement Scenario
7.4.7.6. Australia Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.4.8. Thailand
7.4.8.1. Key Country Dynamics
7.4.8.2. Target Disease Prevalence
7.4.8.3. Competitive Scenario
7.4.8.4. Regulatory Framework
7.4.8.5. Reimbursement Scenario
7.4.8.6. Thailand Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.5. Latin America
7.5.1. SWOT Analysis
7.5.2. Latin America Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.5.3. Brazil
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Competitive Scenario
7.5.3.4. Regulatory Framework
7.5.3.5. Reimbursement Scenario
7.5.3.6. Brazil Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.5.4. Mexico
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Competitive Scenario
7.5.4.4. Regulatory Framework
7.5.4.5. Reimbursement Scenario
7.5.4.6. Mexico Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.5.5. Argentina
7.5.5.1. Key Country Dynamics
7.5.5.2. Target Disease Prevalence
7.5.5.3. Competitive Scenario
7.5.5.4. Regulatory Framework
7.5.5.5. Reimbursement Scenario
7.5.5.6. Argentina Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.6. MEA
7.6.1. SWOT Analysis
7.6.2. MEA Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.6.3. South Africa
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Competitive Scenario
7.6.3.4. Regulatory Framework
7.6.3.5. Reimbursement Scenario
7.6.3.6. South Africa Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.6.4. Saudi Arabia
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Competitive Scenario
7.6.4.4. Regulatory Framework
7.6.4.5. Reimbursement Scenario
7.6.4.6. Saudi Arabia Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.6.5. UAE
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Competitive Scenario
7.6.5.4. Regulatory Framework
7.6.5.5. Reimbursement Scenario
7.6.5.6. UAE Immunohistochemistry Market, 2018 – 2030 (USD Million)
7.6.6. Kuwait
7.6.6.1. Key Country Dynamics
7.6.6.2. Target Disease Prevalence
7.6.6.3. Competitive Scenario
7.6.6.4. Regulatory Framework
7.6.6.5. Reimbursement Scenario
7.6.6.6. Kuwait Immunohistochemistry Market, 2018 – 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1 Company Categorization
8.2 Strategy Mapping
8.2.1 NEW PRODUCT LAUNCH
8.2.2 PARTNERSHIPS
8.2.3 ACQUISITION
8.2.4 COLLABORATION
8.2.5 FUNDING
8.3 Key Company Market Share Analysis, 2022
8.4 Company Profiles
8.4.1 Thermo Fisher Scientific Inc.
8.4.1.1 Company overview
8.4.1.2 Financial performance
8.4.1.3 Product benchmarking
8.4.1.4 Strategic Initiatives
8.4.2 F.Hoffmann-La Roche Ltd.
8.4.2.1 Company overview
8.4.2.2 Financial performance
8.4.2.3 Product benchmarking
8.4.2.4 Strategic Initiatives
8.4.3 Merck KGaA
8.4.3.1 Company overview
8.4.3.2 Financial performance
8.4.3.3 Product benchmarking
8.4.3.4 Strategic Initiatives
8.4.4 Danaher Corporation
8.4.4.1 Company overview
8.4.4.2 Product benchmarking
8.4.4.3 Strategic Initiatives
8.4.5 Perkinelmer, Inc.
8.4.5.1 Company overview
8.4.5.2 Financial performance
8.4.5.3 Product benchmarking
8.4.5.4 Strategic Initiatives
8.4.6 Bio-Rad Laboratories, Inc.
8.4.6.1 Company overview
8.4.6.2 Financial performance
8.4.6.3 Product benchmarking
8.4.6.4 Strategic Initiatives
8.4.7 Cell Signaling Technology Inc.
8.4.8.1 Company overview
8.4.8.2 Financial performance
8.4.8.3 Product benchmarking
8.4.8.4 Strategic Initiatives
8.4.8 Bio SB
8.4.8.1 Company overview
8.4.8.2 Financial performance
8.4.8.3 Product benchmarking
8.4.8.4 Strategic Initiatives
8.4.9 Agilent Technologies, Inc.
8.4.9.1 Company overview
8.4.9.2 Financial performance
8.4.9.3 Product benchmarking
8.4.9.4 Strategic Initiatives
8.4.10 Abcam Plc.
8.4.10.1 Company overview
8.4.10.2 Financial performance
8.4.10.3 Product benchmarking
8.4.10.4 Strategic Initiatives
Chapter 9. KOL Recommendations/ Conclusion
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/